Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK-Reference-Cited by-同舟云学术

Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK

Published:2017-03-02 Issue:9 Volume:129 Page:1155-1165
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kim Ekaterina¹,Hurtz Christian²³,Koehrer Stefan¹⁴,Wang Zhiqiang⁵,Balasubramanian Sriram⁶,Chang Betty Y.⁷,Müschen Markus²,Davis R. Eric⁵,Burger Jan A.¹

Affiliation:

1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;

2. Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA;

3. Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA;

4. Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany;

5. Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX;

6. Janssen Research & Development, LLC, Springhouse, PA;

7. Pharmacyclics, Inc., Sunnyvale, CA

Abstract

Key Points In B-ALL, cells that express a functional pre-BCR ibrutinib abrogate leukemia cell growth in vitro and in vivo. Effects of ibrutinib in B-ALL not only are mediated through inhibition of BTK but also involve BLK inhibition.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/9/1155/1402891/blood722900.pdf

Reference58 articles.

1. Advances in the molecular pathobiology of B-lymphoblastic leukemia;Zhou;Hum Pathol,2012

2. Acute lymphoblastic leukaemia;Inaba;Lancet,2013

3. Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies;Daver;Curr Hematol Malig Rep,2013

4. Targeting pathological B cell receptor signalling in lymphoid malignancies;Young;Nat Rev Drug Discov,2013

5. Bruton’s tyrosine kinase (BTK) inhibitors in clinical trials;Burger;Curr Hematol Malig Rep,2014

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia;Genome Biology;2024-05-31

3. Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL;Blood Advances;2024-05-31

4. CD44: a cancer stem cell marker and therapeutic target in leukemia treatment;Frontiers in Immunology;2024-04-26

5. Proteogenomic profiling uncovers differential therapeutic vulnerabilities between TCF3::PBX1 and TCF3::HLF translocated B-cell acute lymphoblastic leukemia;Haematologica;2024-02-29